Tuesday 20th September 2022
CAR T cells are an exciting and emerging therapy which have been used to treat certain cancers, giving hope to those for whom no other treatments have worked. A recent study carried out in Germany which studied patients with lupus suggests that this therapy could be of use in treating a host of autoimmune conditions including scleroderma.
Wednesday 14th September 2022
Exciting new research run by Professor Liz Walker at the University of Hull and the University of Leeds is aiming to improve oral and dental outcomes for people living with scleroderma, by improving pathways to oral care. You can now get involved in the research team’s study by filling out their short survey about your perspectives on dental and oral care in scleroderma. Find the link on this page!
Friday 9th September 2022
Do you have scleroderma and have a weakened immune system? Would you like to have your say on whether a treatment which can prevent COVID-19 infection is made available to those who have poor immune responses in response to COVID-19 vaccination? Complete our short survey to inform our response to a NICE consultation on whether this treatment should be authorised for use.
Wednesday 7th September 2022
Would you like to find out more about a new study that aims to improve how we understand and treat fibrosis?
Friday 17th September 2021
A series of talks took place throughout the day, covering areas of research funded by SRUK, advice on symptom management, and discussions about the future. This article offers a brief overview of each talk as a taster, and in the coming months they will be made available online.
Wednesday 1st September 2021
OCTAVE study reveals how effective COVID-19 vaccinations are in immunocompromised participants
Tuesday 29th September 2020
An important part of participating in a project such as this is ensuring that you understand how the collected data will be used and why community input is so valuable and fundamentally vital.
Monday 23rd September 2019
Botox surgery is emerging as a form of treatment for Raynaud’s phenomenon, but the reasoning behind why this may work remains unclear. Research evaluating the use of Botulinum toxin type A (BoNT/A), one of the the main ingredients of Botox, has been steadily building since the early 2000s.
Friday 13th September 2019
In an exciting step for scleroderma treatment, the USA’s Food and Drug Administration (FDA) have approved the use of nintedanib in treating interstitial lung disease associated with systemic sclerosis, making this the first therapy for those living with this condition caused by lung fibrosis.
Tuesday 25th September 2018
SRUK have made a significant contribution in providing funding for this two-year pilot study, which is well underway. Initial results are promising, and the success of the study means that the implantable loop recorder can then be examined through a wider clinical study.
